



NDA 020592 S-062
NDA 021086 S-040
NDA 021253 S-048
NDA 022173 S-015
NDA 021520 S-034

SUPPLEMENT APPROVAL

Eli Lilly and Company
Attention: Ashraff Rampersaud, M.S. PMP
Manager, Global Regulatory Affairs-US
Lilly Corporate Center
Indianapolis, IN 46285

Dear Mr. Rampersaud:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received December 21, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zyprexa (olanzapine) Tablets, Zyprexa Zydis (olanzapine) Orally Disintegrating Tablets, Zyprexa Intramuscular (olanzapine) Injection, Zyprexa Relprevv (olanzapine) For Extended Release Injectable Suspension, and Symbyax (olanzapine/fluoxetine) Capsules.

We acknowledge receipt of your amendments dated December 18, 2013, July 9, 2014, November 7, 2014, and December 9, 2014. The December 18, 2013, submission constituted a complete response to our March 8, 2013, action letter.

These "Prior Approval" labeling supplemental new drug applications propose additions and modifications to the WARNING AND PRECAUTIONS section regarding metabolic changes associated with olanzapine.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication

NDA 020592 S-062
NDA 021086 S-040
NDA 021253 S-048
NDA 022173 S-015
NDA 021520 S-034
Page 2

Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Keith Kiedrow, Pharm.D., RAC, Senior Regulatory Project Manager, at (301) 796-1924.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT, USPHS
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
12/19/2014